Discontinued — last reported Q4 '23

Products & Services · Intangible asset impairments

Prevnar 13 - Pediatric — Intangible asset impairments

Pfizer Prevnar 13 - Pediatric — Intangible asset impairments remained flat by 0.0% to $208.50M in Q4 2023 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ4 2023Feb 22, 2024
Rolls up toImpairment Charges
Metric ID: pfe_segment_prevnar_13_pediatric_intangible_asset_impairments

Historical Data

1 years
 FY'23
Value$834.00M

Frequently Asked Questions

What is Pfizer's prevnar 13 - pediatric — intangible asset impairments?
Pfizer (PFE) reported prevnar 13 - pediatric — intangible asset impairments of $208.50M in Q4 2023.